Epithelioid sarcoma: A clinicopathological study of 12 head and neck cases

Oral Dis. 2022 Sep;28(6):1519-1527. doi: 10.1111/odi.13835. Epub 2021 Apr 7.

Abstract

Objectives: To determine the clinicopathological features of epithelioid sarcoma presenting in head and neck region (HNES) and elucidate diagnostic key points and treatment options for HNES.

Materials and methods: A total of 12 HNES cases were collected in our department from 2010 to 2020. Their clinical information and pathological features were documented, and relevant follow-up was performed. Immunohistochemistry was carried to analyze the protein markers of HNES.

Results: Of the 12 HNES cases, 10 were primary tumors and 2 were metastasized from foot and shoulder, respectively. The patients with primary tumors were significantly younger than those with metastasized ones (22.7 vs 41.5, p = .0157), and male patients outnumbered female patients (3:1). Of all HNES cases, 9 were classic subtype, and 3 were proximal subtype. HNES patients had a poor prognosis, with 5-year overall survival of 41.5% and 5-year relapse-free survival of 22.5%. A loss of INI1 was identified as the hallmark of HNES with 83.3% (10/12) of HNES cases presenting as EZH2 positive.

Conclusions: HNES is more prevalent at younger ages and in males, has a poor prognosis, and exhibits a greater proportion of classic subtype than proximal subtype. EZH2 inhibitor has therapeutic potential in HNES.

Keywords: EZH2 inhibitor; INI1; clinicopathological study; epithelioid sarcoma; head and neck region.

MeSH terms

  • Biomarkers
  • Biomarkers, Tumor / metabolism
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Neoplasm Recurrence, Local*
  • SMARCB1 Protein
  • Sarcoma*

Substances

  • Biomarkers
  • Biomarkers, Tumor
  • SMARCB1 Protein